Robert F. Kennedy Jr., President-elect Donald Trump’s nominee for US Department of Health and Human Services, has clarified his stance on weight-loss treatments. While supporting GLP-1 medications in moderation, Kennedy emphasizes the importance of lifestyle changes as the primary approach to weight loss.
Kennedy stated that a balanced diet and regular meals are essential for preventing obesity. He acknowledged that GLP-1 medications have their place but believe they should not be the first line of treatment. Instead, promoting healthy eating habits is the key to addressing the country’s obesity epidemic.
In contrast, billionaire Elon Musk supports making affordable GLP-1 weight-loss medications widely available. Musk believes this would significantly improve public health and quality of life.
Kennedy’s nuanced stance on weight-loss treatments marks a departure from his previous criticism of pharmaceutical solutions. As Health Secretary, Kennedy will oversee the nation’s healthcare policies, including those related to obesity and diabetes treatment.
Source: https://qz.com/rfk-jr-glp-1-ozempic-1851719784